<DOC>
	<DOC>NCT02485119</DOC>
	<brief_summary>The primary objectives of the Phase I study 15404 are to evaluate the safety, tolerability and pharmacokinetics of BAY94-9343 given once every 3 weeks in Japanese subjects with advanced, refractory solid tumors. The secondary objectives are to investigate the efficacy, biomarkers and immunogenicity.</brief_summary>
	<brief_title>Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Maytansine</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Japanese subjects â‰¥ 20 years of age ECOG Performance Status of 0 to 1 Life expectancy of at least 12 weeks Subjects with advanced, histologically or cytologically confirmed solid tumors, not amenable to any standard therapy, have no standard therapy available Subjects whose fresh or archival tumor tissues are available Measurable disease with at least one lesion that can be accurately measured in at least one dimension according to RECIST criteria (Version 1.1 or modified version) Adequate bone marrow, liver, and renal function Anticancer chemotherapy, experimental cancer therapy, or immunotherapy within 2 weeks of start of the first dose Impaired cardiac function or clinically significant cardiac disease (i.e., congestive heart failure (CHF) NYHA Class III or IV) Myocardial infarction or onset of unstable angina &lt; 3 months prior to general screening Cardiac arrhythmias in the electrocardiogram that would interfere with QT/QTc interval measurement (LBBB (left bundle branch block), AV block, atrial fibrillation) QTc &gt;470 ms, derived as the average of the 3 values measured by the ECG recorder's algorithm on the ECG triplicate LVEF (left ventricular ejection fraction) &lt;50 % Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mm Hg and/or diastolic blood pressure &gt; 90 mmHg, despite optimal medical management Known human immunodeficiency virus (HIV) infection Subjects with an active hepatitis B or C infection requiring treatment Personal or family history of Long QT Syndrome (LQTS) Subject with clinically significant eye disorders</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>BAY 94-9343</keyword>
	<keyword>Anetumab ravtansine</keyword>
	<keyword>ADC (Antibody Drug Conjugate)</keyword>
	<keyword>Phase I</keyword>
	<keyword>Japan</keyword>
	<keyword>solid cancers</keyword>
	<keyword>Advanced, refractory solid tumors</keyword>
	<keyword>mesothelin</keyword>
	<keyword>endometrial</keyword>
	<keyword>adenocarcinoma of lung</keyword>
	<keyword>gastrointestinal, ovarian, pancreatic, cholangio, mesothelioma and triple negative breast cancers</keyword>
</DOC>